September 7, 2021 News by Grace Frank Bionews Clinical Will Bring Trials Into ‘Continuum’ of MS Care A new service, Bionews ClinicalĀ is seeking to bring more patients into relevant clinical trials by helping all involved ā scientists, pharmaceutical companies, people with diseases ā regard these studies as part of continuing care. āToday what happens is that the conversation about patients participating in a clinical trial is…
April 28, 2020 News by Grace Frank Surge in Telemedicine One ‘Good’ Outcome from COVID-19 Crisis, Doctors Say While there are few silver linings to the cloud created by COVID-19, the pandemic that has killed tens of thousands, hobbled economies worldwide and drove millions to quarantine in their homes, one may be a new appreciation of telemedicine. “If something good could come out of this crisis, it’s that…
November 15, 2019 News by Grace Frank CHMP Favors Mayzent as Oral Treatment Specifically for Active SPMS Patients in EU The Committee for Medicinal Products for Human Use (CHMP) issued an opinion supporting MayzentĀ (siponimod) as an oral treatment specifically for adults with active secondary progressive multiple sclerosisĀ (SPMS) in the European Union. Opinions released by CHMP, an arm of the European Medicines Agency (EMA), carry weight and are…
November 14, 2019 News by Grace Frank Vumerity’s $88,000 List Price Not What ‘We Had Hoped,’ National MS Society Says The National Multiple Sclerosis Society has criticized BiogenĀ for the $88,000 yearly list price it placed onĀ VumerityĀ (diroximel fumarate), the newly approved oral disease-modifying treatment (DMT) for relapsing multiple sclerosis. That criticism extends to repeated price increases withĀ TecfideraĀ (dimethyl fumarate), Biogen’s similar oral DMT for…
October 9, 2019 News by Grace Frank US Supreme Court Denies Acorda Appeal on Ampyra Patents, Supporting Generic Versions The U.S. Supreme Court gave a green light to generic versions of Ampyra this week, declining to hearĀ Acorda Therapeutics‘ appeal of a lower court ruling that allowed generics of its treatment for walking or gait problems in multiple sclerosis. That lower court rulingĀ came fromĀ the U.S. District Court…